Live Investor Briefing – Prescient Therapeutics

Prescient Therapeutics (ASX-PTX)
Live Investor Briefing

Register for an Upcoming Session

Please join Prescient Therapeutics CEO Steven Yatomi-Clarke for a special live investor briefing.

Event Details:

Date: Register for an Upcoming Session

In the session, Steven will discuss:

  • The company’s promising pipeline of cancer treatments with two targeted therapies, cell therapy enhancements and CAR-T;
  • Its work in the most exciting area of cancer research “next gen” CAR-T and its OmniCAR platform;
  • Strong balance sheet with $20m in the bank following oversubscribed Share Purchase Plan and Placement.

This is a live and interactive session, you simply need an internet connection to participate. Don’t miss out, spots are limited – This is a FREE event.

Book Your Spot

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets have been engaged to help manage our investor communications.

What is a 708 investor?

FEATURE SPEAKER

Steven Yatomi-Clarke (Speak feature)

Steven Yatomi-Clarke

CEO and Managing Director

Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.